ストックスクリーナーアプリを入手
5.025
0.89%
-0.035
Myriad Genetics Inc (MYGN) 最新ニュース
3 Reasons to Sell MYGN and 1 Stock to Buy Instead - Yahoo Finance
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care By Investing.com - Investing.com Canada
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know - Finviz
Insider Buying: Samraat Raha Acquires 40,000 Shares of Myriad Ge - GuruFocus
Myriad Genetics (NASDAQ:MYGN) CEO Purchases $200,000.00 in Stock - MarketBeat
Raha, Myriad Genetics CEO, buys $199k in shares - Investing.com India
Trading Systems Reacting to (MYGN) Volatility - Stock Traders Daily
Trading Recap: Whats next for Myriad Genetics Inc stockBreakout Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Take Profit: What hedge funds are buying Myriad Genetics IncMarket Sentiment Review & Weekly High Momentum Picks - baoquankhu1.vn
Royce & Associates LP Makes New $4.84 Million Investment in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Stock Up on New Breast Cancer MRD Test Launch | 2026News and Statistics - IndexBox
MYGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why - Finviz
Myriad Commercially Launches Precise MRD with Select Community Oncologists - Bitget
Myriad Genetics (MYGN) CPO has shares withheld to cover taxes - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by Zacks Research - MarketBeat
MYGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Director S. Louise Phanstiel Buys 48,000 Shares - MarketBeat
Insider Buying: Myriad Genetics (NASDAQ:MYGN) Director Acquires 6,100 Shares of Stock - MarketBeat
S. Louise Phanstiel Acquires 50,407 Shares of Myriad Genetics (NASDAQ:MYGN) Stock - MarketBeat
Myriad Genetics Insider Bought Shares Worth $494,722, According to a Recent SEC Filing - marketscreener.com
Director Phanstiel adds 104,507 Myriad Genetics (MYGN) shares - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating a 60% Upside Potential Amidst Financial Challenges - DirectorsTalk Interviews
How Myriad Genetics Inc. (MYGN) Affects Rotational Strategy Timing - Stock Traders Daily
Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN) - The Globe and Mail
GXD-Bio Appeals Genetic Tester IP Loss Against Myriad - Law360
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy - MSN
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Inc files for mixed shelf of up to $200 millionSEC filing - marketscreener.com
Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 MillionSEC Filing - TradingView
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead By Investing.com - Investing.com South Africa
Cancer, prenatal and mental health tests anchor Myriad (MYGN) 2025 plan - Stock Titan
MYGN: UBS Maintains Neutral Rating, Lowers Price Target to $6.00 - GuruFocus
MYGN: Wells Fargo Lowers Price Target for Myriad Genetics | MYGN Stock News - GuruFocus
Why Myriad Genetics (MYGN) Stock Is Trading Up Today - Finviz
Myriad Genetics (MYGN) Unveils New Data on Cancer Diagnostics at ASCO-GU 2026 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $6 From $8, Maintains Neutral Rating - marketscreener.com
Wells Fargo & Company Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00 - MarketBeat
Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth - Seeking Alpha
Myriad Genetics Q4 2025 slides: profitability improves, MRD launch ahead - Investing.com Nigeria
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad's Precise MRD, Prolaris, and MyRisk tests - Bitget
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests - The Manila Times
Myriad cancer tests at ASCO-GU challenge prostate risk rules - Stock Titan
Myriad Genetics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down - TradingView
Myriad Genetics (MYGN) Stock Surges on Earnings Beat and Revenue Goals - GuruFocus
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y (MYGN:NASDAQ) - Seeking Alpha
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution - The Manila Times
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Sur - GuruFocus
Myriad Genetics Reports Strong Q4 2025 Earnings and Growth Outlook - Intellectia AI
Here's what key metrics tell us about Myriad (MYGN) Q4 earnings - MSN
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings - Yahoo Finance
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates - Nasdaq
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript - The Globe and Mail
Myriad Genetics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Myriad Genetics Q4 2025 beats EPS forecast, stock rises - Investing.com Australia
Myriad Genetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
0.87%
0.87%
大文字化:
|
ボリューム (24 時間):